UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FRI-07 Modern systemic drug therapies in breast cancer in 2013

Digestive and liver disease, 2013-04, Vol.45, p.S244-S244

Zielinski, C.C

2013

Volltextzugriff (PDF)

The landscape of medical oncology in Europe by 2020

Annals of oncology, 2014-02, Vol.25 (2), p.525-528

2014

Volltextzugriff (PDF)

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Lung cancer (Amsterdam, Netherlands), 2009-05, Vol.64 (2), p.211-218

2009

Volltextzugriff (PDF)

2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases

European journal of cancer (1990), 2015-09, Vol.51, p.S593-S593

2015

Volltextzugriff (PDF)

2927 Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas

European journal of cancer (1990), 2015-09, Vol.51, p.S593-S593

2015

Volltextzugriff (PDF)

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

Annals of oncology, 2012-08, Vol.23 Suppl 6, p.vi46-vi51

2012

Volltextzugriff (PDF)

2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases

European journal of cancer (1990), 2015-09, Vol.51, p.S592-S592

2015

Volltextzugriff (PDF)

447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial

European journal of cancer (1990), 2015-09, Vol.51, p.S94-S94

2015

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of oncology, 2022-04, Vol.33 (4), p.406-415

2022

Volltextzugriff (PDF)

45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S54-S54

2012

Volltextzugriff (PDF)

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

European journal of cancer (1990), 2011, Vol.47, p.S346-S346

2011

Volltextzugriff (PDF)

7106 POSTER DISCUSSION The Proteasome-inhibitor Bortezomib is Active in Human Urothelial Cancer Cell Lines in Combination With the Tyrosine-kinase Inhibitor Sunitinib or Cisplatinum

European journal of cancer (1990), 2011, Vol.47, p.S506-S506

2011

Volltextzugriff (PDF)

5061 POSTER Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer

European journal of cancer (1990), 2011, Vol.47, p.S348-S348

2011

Volltextzugriff (PDF)

22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases

Annals of oncology, 2022-03, Vol.33, p.S11-S12

2022

Volltextzugriff (PDF)

1421P Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)

Annals of oncology, 2024-09, Vol.35, p.S886-S886

2024

Volltextzugriff (PDF)

Third consensus on medical treatment of metastatic breast cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1771-1785

2009

Volltextzugriff (PDF)

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

Annals of oncology, 2023-09, Vol.34 (9), p.734-771

2023

Volltextzugriff (PDF)

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Annals of oncology, 2013-07, Vol.24 (7), p.1769-1777

2013

Volltextzugriff (PDF)

Characterisation of oncologic patient visits at the ED at an Austrian tertiary care center

Annals of oncology, 2018-10, Vol.29, p.viii626-viii626

2018

Volltextzugriff (PDF)

1840P - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers

Annals of oncology, 2019-10, Vol.30, p.v746-v746

2019

Volltextzugriff (PDF)

Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers

Annals of oncology, 2019-10, Vol.30, p.v746

2019

Volltextzugriff (PDF)

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease

Annals of oncology, 2010-05, Vol.21 (5), p.917-924

2010

Volltextzugriff (PDF)

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Annals of oncology, 2014-02, Vol.25 (2), p.366-371

2014

Volltextzugriff (PDF)

virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

Breast cancer research and treatment, 2010-02, Vol.119 (3), p.673-683

2010

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(109)

Sprache

Englisch
(109)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Humans
(34)
Oncology
(27)
Biological And Medical Sciences
(26)
Medical Sciences
(25)
Female
(24)
Hematology, Oncology And Palliative Medicine
(21)
Middle Aged
(16)
Male
(15)
Pharmacology. Drug Treatments
(15)
Tumors
(15)
Adult
(14)
Aged
(13)
Antineoplastic Agents
(13)
Chemotherapy
(8)
Gynecology. Andrology. Obstetrics
(8)
Mammary Gland Diseases
(8)
Aged, 80 And Over
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

FRI-07 Modern systemic drug therapies in breast cancer in 2013

The landscape of medical oncology in Europe by 2020

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases

2927 Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases

447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

7106 POSTER DISCUSSION The Proteasome-inhibitor Bortezomib is Active in Human Urothelial Cancer Cell Lines in Combination With the Tyrosine-kinase Inhibitor Sunitinib or Cisplatinum

5061 POSTER Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer

22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases

1421P Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)

Third consensus on medical treatment of metastatic breast cancer

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Characterisation of oncologic patient visits at the ED at an Austrian tertiary care center

1840P - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers

Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

Suchergebnisse filtern